Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2021

View Archived Issues

New CRISPR-Cas vector designs reduce vector size and increase vector titer for HIV/AIDS treatment

Studies show NNRTI MK-8507 can be used with islatravir, levonorgestrel/ethinyl estradiol

FDA approves IND for phase I/II study of Zofin in COVID-19 long haulers

FDA clears IND for Viracta's all-oral combination regimen in EBV-positive solid tumors

Positive data reported from phase Ib study of IMT-002 in T1D with HLA-DQ8 trait

Medshine Discovery patents new KHK inhibitors for NASH

Sorrento initiates dosing in U.K. phase II study of COVI-DROPS in outpatient setting

Positive phase II data for eprenetapopt plus azacitidine in TP53 mutant MDS and AML

IRF7 and PTDSS2 are therapeutic targets in HIV-1 infection

IFM Due divulges hSTING antagonists

Tyra Biosciences presents new FGFR inhibitors

R-107 shows the ability to prevent, treat and reverse established PAH in vivo

Rheos Medicines discloses MALT1 inhibitors

Apoptosis inhibitors show promise in severe TB models

Eureka initiates phase I/II ARYA-3 study of ECT-204 in liver cancer

Dicerna provides interim data from phase I study of belcesiran in AATLD

XPB shown to regulate HIV-1 transcriptional activity

Antengene obtains HREC approval in Australia for phase I study of ATG-101 in solid tumors and NHL

Addition of CF-296 to SOC leads to enhanced antibacterial activity against MSSA and MRSA isolates

Amplia reports phase I data on AMP-945

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...